The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SNGX | -48.25% | -99.73% | -69.3% | -100% |
| S&P | +12.66% | +85.37% | +13.13% | +1,741% |
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
No news articles found for Soligenix.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | 42.7% |
| Market Cap | $4.97M | -45.1% |
| Market Cap / Employee | $0.31M | 0.0% |
| Employees | 16 | 6.7% |
| Net Income | -$2.53M | -47.2% |
| EBITDA | -$2.58M | -38.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.53M | 7.0% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.27M | 2272.8% |
| Short Term Debt | $0.11M | -94.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -105.25% | -40.1% |
| Return On Invested Capital | 11.70% | 87.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.93M | -0.8% |
| Operating Free Cash Flow | -$2.93M | -0.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.04 | 1.31 | 1.15 | 2.22 | 44.79% |
| Price to Tangible Book Value | 1.04 | 1.31 | 1.15 | 2.22 | 44.79% |
| Enterprise Value to EBITDA | -0.12 | 0.20 | 0.14 | 1.98 | -432.39% |
| Return on Equity | -249.0% | -437.7% | -402.2% | -169.3% | 21.12% |
| Total Debt | $1.48M | $0.08M | $0.41M | $0.39M | -82.52% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
